Improvement of Sleep in a Parkinson's Disease Patient with Foslevodopa/Foscarbidopa Infusion
Author Information
Author(s): Sakuramoto Hirotaka, Fujita Hiroaki, Ogaki Keitaro, Suzuki Keisuke
Primary Institution: Dokkyo Medical University
Hypothesis
Can continuous subcutaneous infusion of foslevodopa/foscarbidopa improve sleep status in Parkinson's disease patients?
Conclusion
The treatment improved motor symptoms and sleep architecture in the patient.
Supporting Evidence
- After treatment, the patient's MDS-UPDRS part III score improved from 63 to 48.
- The off time decreased from 15 hours to 6 hours.
- Total sleep time increased from 179 minutes to 412 minutes after treatment.
- Sleep efficiency improved from 38% to 71.5%.
Takeaway
A patient with Parkinson's disease slept better after receiving a new treatment that helps with their symptoms.
Methodology
The patient's sleep status was measured using a portable electroencephalography/electrooculography system before and after treatment.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
50-year-old male with a 9-year history of Parkinson's disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website